Defensin promotes the binding of lipoprotein(a) to vascular matrix

Blood

Volumn 94, Issue 6, 1999, Pages 2007-2019

  Bdeir, Khalil ^b   Cane, William ^b   Canziani, Gabriela ^b   Chaiken, Irwin ^b   Weisel, John ^b   Koschinsky, Marlys L ^b   Lawn, Richard M ^b   Bannerman, Peter G ^b   Sachais, Bruce S ^b   Kuo, Alice ^b   Hancock, Mark A ^b   Tomaszewski, John ^b   Raghunath, P N ^b   Ganz, Tomas ^b   Higazi, Abd Al Roof ^b   Cines, Douglas B ^a  

^a Laboratory Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DEFENSIN; FIBRONECTIN; HEPARIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VITRONECTIN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BIOSENSOR; COMPLEX FORMATION; ENDOTHELIUM CELL; GEL FILTRATION; HUMAN; IMMUNOELECTRON MICROSCOPY; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION;

EID: 0033568156     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801, 1993
2. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP: Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 276:544, 1996
3. Assmann G, Schulte H, von Eckardstein A: Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 77:1179, 1996
4. Ridker PM, Stampfer MJ, Hennekens CH: Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 273:1269, 1995
5. Williams KJ, Tabas I: The response-to-retetention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15:551, 1995
6. Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE, Smith R: Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol 16:471, 1996
7. Lin S-J, Jan K-M, Weinbaum S, Chien S: Tranendothelial transport of low density lipoprotein in association with cell mitosis in rat aorta. Arteriosclerosis 9:230, 1989
8. Schwenke DC, Carew TE: Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II: Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis 9:908, 1989
9. Nielen LB, Stender S, Jauhiainen M, Nordestgaard BG: Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesional rabbit aorta. J Clin Invest 98:563, 1996
10. Saxena U, Klein MG, Vanni TM, Goldberg U: Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix. J Clin Invest 89:373, 1992
11. Syrovets T, Thillet J, Chapman J, Simmet T: Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes. Blood 90: 2027, 1997
12. Fruebis J, Steinberg D, Dresel HA, Carew TE: A comparison of the antiatherogenic effects of Probucol and of a structural analogue of Probucol in low density lipoprotein receptor-deficient rabbits. J Clin Invest 94:392, 1994
13. Liu AC, Lawn RM: Vascular interactions of Lp(a). Curr Opin Lipidol 5:269, 1994
14. McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 300:132, 1987
15. van der Hoek YY, Wittekoek ME, Beisiegel U, Kastelein JJP, Koschinsky ML: The apolipoprotein(a) kringle IV repears which differ from the major repeat kringles are present in variably-sized isoforms. Hum Mol Genet 2:361, 1993
16. Gabel BR, Koschinsky ML: Sequences within apolipoprotein(a) kringle IV types 6-8 bind diretly to low-density lipoprotein and mediate noncovalent association of apolipoprotein(a) with apolipoprotein B-100. Biochemistry 37:7892, 1998
17. Brunner C, Kraft HG, Utermann G, Muller HJ: Cys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci USA 90:11643, 1993
18. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF: A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 339:301, 1989
19. Hajjar KA, Gavish D, Breslow JL, Nachman RL: Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339:303, 1989
20. Loscalzo J, Weinfeld M, Fless GM, Scanu AM: Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 10:240, 1990
21. Pillarisetti S, Paka L, Obunike JC, Berglund L, Goldberg IJ: Subendothelial retention of lipoprotein(a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest 100:867, 1997
22. Pekelharing HLM, Kleinveld HA, Duff PFCCM, Bouma BN, van Rijn HJM: Effect of lipoprotein (a) and LDL on plasminogen binding to extracellular matrix and on matrix-dependent plasminogen activation by tissue plasminogen activator. Thromb Haemost 75:497, 1996
23. Klezovitch O, Edelstein C, Scanu AM: Evidence that the fibrinogen binding domain of apo(a) is outside the lysine binding site of kringle IV-10. A study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes. J Clin Invest 98:185, 1996
24. LoGrasso PV, Cornell-Kennon S, Boettcher BR: Cloning, expression, and characterization of human apolipoprotein (a) kringle IV37. J Biol Chem 269:21820, 1994
25. Scanu AM: Identification of mutations in human apolipoprotein(a) kringle 4-37 from the study of the DNA of peripheral blood lymphocytes: Relevance to the role of lipoprotein(a) in atherothrombosis. Am J Cardiol 75:588, 1995
26. Boonmark NW, Lous XJ, Yang ZJ, Schwartz K, Zhang J-L, Rubin EM, Lawn RM: Modification of apoplipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 100:558, 1997
27. Hughes SD, Lou XJ, Ighani S, Verstuyft J, Grainger DJ, Lawn RM, Rubin EM: Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest 100:1493, 1997
28. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC: Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1:256, 1995
29. Sangrar W, Gabel BG, Boffa MB, Walker JB, Hancock MA, Marcovina SM, Horrevoets AJG, Nesheim ME, Koschinsky ML: The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface. Biochemistry 36:10353, 1997
30. Liu J, Harpel PC, Gurewich V: Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin. Biochemistry 33:2554, 1994
31. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC: Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 370:460, 1994
32. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A: The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med 1:74, 1995
33. Ridker PM: Inflammation, infection, and cardiovascular risk. How good is the clinical evidence? Circulation 97:1671, 1997
34. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 17:1121, 1997
35. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M: Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 92:8264, 1995
36. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973, 1997
37. Weijemberg MP, Feskens EJM, Kromhout D: White blood cell count and the risk of coronary heart disease and all cause mortality in elderly men. Arterioscler Thromb Vasc Biol 16:499, 1996
38. Zalokar JB, Richard JL, Claude JR: Leukocyte count, smoking and myocardial infarction. N Engl J Med 304:465, 1981
39. Ganz T: Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes. Infect Immun 55:568, 1987
40. Harwig SS, Ganz T, Lehrer RI: Neutrophil defensins: Purification, characterization, and antimicrobial testing. Methods Enzymol 236:160, 1994
41. Panyutich AV, Panyutich EA, Krapivin VA, Baturevich EA, Ganz T: Plasma defensin concentrations are elevated in patients with sepsis or bacterial meningitis. J Lab Clin Med 122:202, 1993
42. Ihl T, Nakazato N, Matsukura S: Elevated concentrations of human neutrophil peptides in plasma, blood, and body fluids from patients with infection. Clin Infect Dis 25:1134, 1997
43. Selsted ME, Harwig SSL, Ganz T, Schilling JW, Lehrer RI: Primary structures of three human neutrophil defensins. J Clin Invest 76:1436, 1985
44. Hill CP, Yee J, Selsted ME, Eisenberg D: Crystal structure of defensin HNP-3, an amphiphilic dimer: Mechanisms of membrane permeabilization. Science 251:1481, 1991
45. Boren J, Olin K, Lee I, Chait A, Wight TM, Innerarity TL: Identification of the principal proteoglycan binding site in LDL. A single point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest 101:2658, 1998
46. Fass D, Blacklow S, Kim PS, Berger JM: Molecular basis of familial hypercholesterolaemia from structure of LDL receptor molecule. Nature 388:691, 1997
47. Barnathan ES, Reghunath PN, Tomaszewski JE, Ganz T, Cines DB, Higazi AA: Immunohistochemical localization of defensin in human coronary vessels. Am J Pathol 150:1009, 1997
48. Higazi AA-R, Lavi E, Bdeir K, Ulrich AM, Jamieson DG, Rader DJ, Usher DC, Kane W, Ganz T, Cines DB: Defensin stimulates the binding of Lp(a) to human vascular endothelial and smooth muscle cells. Blood 89:4290, 1997
49. Higazi AA-R, Barghouti II, Abu-Much R: Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. J Biol Chem 270:9472, 1995
50. Higazi AA-R, Ganz T, Kariko K, Cines DB: Defensin modulates tPA and plasminogen binding to fibrin and endothelial cells. J Biol Chem 271:17650, 1996
51. Rader DJ, Mann WA, Cain W, Kraft H-G, Usher D, Zech LA, Hoeg JM, Davignon J, Lupien P, Grossman M, Wilson JM, Brewer HB Jr: The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 95:1403, 1995
52. Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK: The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediates by the VLDL receptor. J Clin Invest 100:2170, 1997
53. Panyutich AV, Voitenok NN, Lehrer RI, Ganz T: An enzyme immunoassay for human defensin. J Immmunol Methods 141:149, 1991
54. Rader DJ, Cain W, Zech L, Usher D, Brewer HB: The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 93:2758, 1994
55. Edelstein CJ, Italia J, Klezovitch O, Scanu A: Functional and metabolic differences between elastase-generated fragments of human lipoprotein(a) and apolipoprotein(a). J Lipid Res 37:1786, 1996
56. Bilheimer DW, Eisenberg S, Levy RI: The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochem Biophys Acta 260:212, 1972
57. Liu SY, Choy S, Dembinski TC, Hatch GM, Mymin D, Shen GX, Angel A, Choy PC, Man RYK: Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: Relationship to endothelium dependent relaxation. Cardiovasc Res 28:1476, 1994
58. Harats D, Dabach D, Hollander G, Ben-Naim M, Schwartz R, Berry EM, Stein O, Stein Y: Fish oil ingestion in smokers and nonsmokers enhances peroxidation of plasma lipoproteins. Atherosclerosis 90:127, 1991
59. Koschinsky ML, Tomlinson JE, Zioncheck TF, Schwartz K, Eaton DL, Lawn RM: Apolipoprotein(a): Expression and characterization of a recombinant form of the protein in mammalian cells. Biochemistry 30:5044, 1991
60. Cines DB, Lyss AP, Reeber MJ, Bina M, DeHoratius R: Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus. J Clin Invest 73:611, 1984
61. Esko JD: Genetic analysis of proteoglycan structure, function and metabolism. Curr Opin Cell Biol 3:805, 1991
62. Gospodarowicz D, Delgado D, Vlodavsky I: Permissive effect of the extracellular matrix on cell proliferation. Proc Natl Acad Sci USA 77:4094, 1980
63. Myszka DG: Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Curr Opin Biotechnol 8:50, 1997
64. Johnsson B, Lofas S, Lindquist G, Edstrom A, Muller-Hillgran R-M, Hanson A: Comparison of methods for immobilization to carboxymethyl dextran sensor surfaces by analysis of the specific activity of monoclonal antibodies. J Mol Recognition 8:125, 1995
65. Stenberg E, Prrsson B, Roos H, Urbaniczky C: Quantitative determination of surface concentration of protein with surface plasmon resonance by using radiolabeled proteins. Colloid Interface Sci 143: 513, 1991
66. Karlsson R, Roos H, Fagerstam L, Mattson L: Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytic system. Methods Companion Methods Enzymol 6:99, 1994
67. Veklich YI, Gorkun OV, Medved LV, Niewenhuizen W, Wiesel JW: Carboxyterminal portions of the alpha chains of fibrinogen and fibrin: Localization by electron microscopy and the effects of isolated alpha-C fragments on polymerization. J Biol Chem 268:13577, 1993
68. Weisel JW, Stauffacher CV, Bullit E, Cohen C: A model for fibrinogen: Domains and sequence. Science 230:1388, 1985
69. Poon M, Zhang Z, Dunsky KG, Taubman MB, Harpel PC: Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 96:2514, 1997
70. Rader DJ, Hoeg JM, Brewer HB Jr: Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 120:1012, 1994
71. Soong LB, Ganz T, Ellison A, Caughey GH: Purification and characterization of defensins from cystic fibrosis sputum. Inflamm Res 46:98, 1997
72. Ashitani J, Mukae H, Nakazato M, Taniguchi H, Ogawa K, Kohno S, Matsukura S: Elevated pleural fluid levels of defensins in patients with empyema. Chest 113:788, 1998
73. Liu J-N, Kung W, Harpel PC, Gurewich V: Demonstration of covalent binding of lipoprotein(a) [Lp(a)] to fibrin and endothelial cells. Biochemistry 37:3949, 1998
74. White SH, Wimley WC, Selsted ME: Structure, function and membrane integration of defensins. Curr Opin Struct Biol 5:521, 1995
75. Van der Hoek Y, Sangarar W, Cote GP, Kastelein JP, Koschinsky M: Binding of recombinant apo(a) to extracellular matrix proteins. Arterioscler Thromb 14:1792, 1994
76. Salonen E-M, Jauhiaianen M, Zardi L, Vaheri A, Ehnholm C: Lipoprotein (a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO J 8:4035, 1989
77. Ugarova TP, Zamarron C, Veklich Y, Bowditch RD, Ginsburg MH, Weisel JW, Plow EF: Conformational transitions in the cell binding domain of fibronectin. Biochemistry 34:4457, 1995
78. Lichtenstein A: Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. J Clin Invest 88:93, 1991
79. Okrent DG, Lichtenstein AK, Ganz T: Direct cytotoxicity of polymorphonuclear leukocyte granule proteins to human lung-derived cells and endothelial cells. Am Rev Resp Dis 141:179, 1990